tradmap

ADPT Adaptive Biotechnologies Corp

$24.57 -0.34%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Adaptive Biotechnologies Corp (ADPT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3.9 billion. Shares last traded at $24.57, 8.6% below their 52-week high. Over the past year the stock is up 91.3%. Net profit margin is -20.7%, below the peer median of 5.3%. Revenue grew 54.8% year over year.

Market Cap
$3.9B
Shares Out
159.6M
EPS (TTM)
$-1.18
P/E Ratio
P/S Ratio
12.73
P/B Ratio
27.44
Dividend / Share
Dividend Yield
52-Week High
$26.87
52-Week Low
$12.01
Volume
107,970
Avg Vol (3m)
182,305.556

Performance

1W
-7.04%
1M
-0.12%
3M
+35.71%
6M
+54.29%
YTD
+54.53%
1Y
+91.28%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.64
SMA (50)
$23.38
SMA (200)
$17.64
Price vs SMA50
+5.07%
Price vs SMA200
+39.31%
ATR (14)
$1.14

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$308M
Net Income
$-64M
Gross Margin
75.6%
Operating Margin
-12.2%
Net Margin
-20.7%
Return on Equity
-44.7%
Return on Assets
-10.0%
Current Ratio
4.79
Debt / Equity
0.00
Revenue Growth (YoY)
+54.8%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.38 2026-08-04
Q1 2026 $-0.13 2026-05-05
FY 2025 $-0.39 2026-02-26
Q3 2025 $-0.30 2025-11-05
Q2 2026 $-0.37 2026-08-04
Q1 2026 $-0.20 2026-05-05

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ADPT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
12.73 / 19.49 med
-35% discount
Net margin vs peers
-20.7% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.